NYSE:RMD - ResMed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $106.80 -0.04 (-0.04 %) (As of 08/19/2018 09:06 AM ET)Previous Close$106.80Today's Range$106.25 - $107.2452-Week Range$72.49 - $109.97Volume755,135 shsAverage Volume692,679 shsMarket Capitalization$15.38 billionP/E Ratio30.25Dividend Yield1.38%Beta0.89 Company ProfileAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. Receive RMD News and Ratings via Email Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNYSE:RMD CUSIP76115210 Webwww.resmed.com Phone858-836-5000 Debt Debt-to-Equity Ratio0.13 Current Ratio2.08 Quick Ratio1.56 Price-To-Earnings Trailing P/E Ratio30.25 Forward P/E Ratio29.18 P/E Growth2.78 Sales & Book Value Annual Sales$2.34 billion Price / Sales6.51 Cash Flow$4.3574 per share Price / Cash24.51 Book Value$14.43 per share Price / Book7.40 Profitability EPS (Most Recent Fiscal Year)$3.53 Net Income$315.58 million Net Margins13.49% Return on Equity24.74% Return on Assets14.85% Miscellaneous Employees6,080 Outstanding Shares142,740,000Market Cap$15.38 billion ResMed (NYSE:RMD) Frequently Asked Questions What is ResMed's stock symbol? ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD." How often does ResMed pay dividends? What is the dividend yield for ResMed? ResMed declared a quarterly dividend on Thursday, August 2nd. Stockholders of record on Thursday, August 16th will be paid a dividend of $0.37 per share on Thursday, September 20th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.39%. The ex-dividend date of this dividend is Wednesday, August 15th. This is a positive change from ResMed's previous quarterly dividend of $0.35. View ResMed's Dividend History. How were ResMed's earnings last quarter? ResMed Inc. (NYSE:RMD) released its quarterly earnings data on Thursday, August, 2nd. The medical equipment provider reported $0.95 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.95. The medical equipment provider earned $623.63 million during the quarter, compared to analyst estimates of $622.78 million. ResMed had a net margin of 13.49% and a return on equity of 24.74%. The company's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the company posted $0.77 EPS. View ResMed's Earnings History. When is ResMed's next earnings date? ResMed is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for ResMed. What price target have analysts set for RMD? 11 brokers have issued 1-year target prices for ResMed's stock. Their predictions range from $55.00 to $90.00. On average, they expect ResMed's stock price to reach $68.80 in the next twelve months. This suggests that the stock has a possible downside of 35.6%. View Analyst Price Targets for ResMed. What is the consensus analysts' recommendation for ResMed? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ResMed. Who are some of ResMed's key competitors? Some companies that are related to ResMed include Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD) and Novocure (NVCR). Who are ResMed's key executives? ResMed's management team includes the folowing people: Mr. Michael J. Farrell BE, SM, MBA, Chief Exec. Officer and Director (Age 46)Mr. Robert A. Douglas, Pres & COO (Age 58)Mr. Brett A. Sandercock, Chief Financial Officer (Age 51)Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 59)Mr. James Hollingshead, Pres of Sleep Bus. (Age 55) Has ResMed been receiving favorable news coverage? News coverage about RMD stock has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ResMed earned a coverage optimism score of 0.23 on Accern's scale. They also assigned news articles about the medical equipment provider an impact score of 48.16 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for ResMed. Who are ResMed's major shareholders? ResMed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.67%), FMR LLC (5.66%), Baillie Gifford & Co. (3.38%), Bank of New York Mellon Corp (1.14%), Congress Asset Management Co. MA (0.69%) and Morgan Stanley (0.68%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed. Which major investors are selling ResMed stock? RMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., NN Investment Partners Holdings N.V., Janus Henderson Group PLC, Bank of New York Mellon Corp, Baillie Gifford & Co., Congress Asset Management Co. MA and Legal & General Group Plc. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed. Which major investors are buying ResMed stock? RMD stock was purchased by a variety of institutional investors in the last quarter, including Los Angeles Capital Management & Equity Research Inc., Morgan Stanley, Canada Pension Plan Investment Board, Standard Life Aberdeen plc, Renaissance Technologies LLC, Schwab Charles Investment Management Inc., Capital Fund Management S.A. and Mackay Shields LLC. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert and Warren Russell Hawkins. View Insider Buying and Selling for ResMed. How do I buy shares of ResMed? Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ResMed's stock price today? One share of RMD stock can currently be purchased for approximately $106.80. How big of a company is ResMed? ResMed has a market capitalization of $15.38 billion and generates $2.34 billion in revenue each year. The medical equipment provider earns $315.58 million in net income (profit) each year or $3.53 on an earnings per share basis. ResMed employs 6,080 workers across the globe. How can I contact ResMed? ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected] MarketBeat Community Rating for ResMed (NYSE RMD)Community Ranking: 1.6 out of 5 ()Outperform Votes: 237 (Vote Outperform)Underperform Votes: 503 (Vote Underperform)Total Votes: 740MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/19/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?